Mannkind slides ahead of FDA decision

ValBrickates Kennedy

BOSTON (MarketWatch) -- Shares of Mannkind Corp.
MNKD, -0.14%
were down 7% in afternoon trading. The U.S. Food and Drug Administration is expected to decide on whether to approve the company's new inhaled insulin product Afrezza by Jan. 26.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.